TRIM33 and dermatomyositis: In a retrospective, multicenter cohort study, Fiorentino, Mecoli, et al. (6) identified autoantibodies present in patients with anti–TIF1-γ–positive DM that conferred protection against cancer development, with a dose-response relationship between increasing number of autoantibodies and decreasing cancer frequency (6).